Fermenta Receives FSSAI Approval for Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green®) for Health Supplements, Nutraceuticals and Food Products

▴ Mr. Prashant Nagre, Managing Director, Fermenta Biotech Limited
Reinforces Fermenta’s leadership in science-backed Vitamin D3 solutions and its commitment to addressing India’s widespread Vitamin D deficiency

Mumbai, 06 July 2026: Fermenta Biotech Limited, India’s leading manufacturer of premium-grade APIs, intermediates, and nutritional premixes for the global markets, today announced that its Vitamin D3 (Cholecalciferol) - Plant Source (VITADEE Green®) has received approval from the Food Safety and Standards Authority of India (FSSAI) for use as an ingredient in Health Supplements, Nutraceuticals and Food Products.

The approval allows Indian food and supplement manufacturers to use VITADEE Green® in fortified staple foods, food and beverages, dietary supplements and nutraceuticals, addressing one of the most pressing gaps in the country’s nutritional landscape. Studies estimate that a large percentage of the Indian population has suboptimal Vitamin D levels, a deficiency increasingly linked to urbanisation, indoor lifestyles and limited sun exposure despite the country’s geography.

Comment from Prashant Nagre – Managing Director

“Vitamin D deficiency remains a widespread public health concern in India, and the demand for sustainable nutrition continues to grow rapidly. The FSSAI approval allows us to bring VITADEE Green® directly to Indian food fortification and nutraceutical manufacturers, helping bridge the nutrition gap for the country’s large population.

As one of the first Indian companies to develop and patent a sustainable, scalable and affordable plant-source Vitamin D3 process, we are well placed to tackle the deficiency at a national level. Developed and manufactured in India, VITADEE Green® also supports the Make in India vision by offering a self-reliant domestic option for Indian formulators. Crucially, VITADEE Green® offers Indian formulators the superior D3 form in a fully plant-sourced format, rather than the Vitamin D2 they have often had to settle for. This is a meaningful step in our commitment to delivering differentiated, science-validated and sustainable solutions that create lasting value for our customers and for society.”

For India’s vegetarian consumers, who have had limited access to a plant-source Vitamin D3, the development brings a domestically manufactured, regulatory-cleared option to the market. It also supports the broader national objective of addressing Vitamin D deficiency through food fortification, an area where regulators have increasingly favoured plant-based sources.

About Fermenta

Fermenta Biotech Limited (www.fermentabiotech.com) delivers best-in-class, science-validated nutritional ingredients, green chemistry and environmental solutions across pharmaceuticals, dietary supplements, food & beverage, veterinary, and animal nutrition industries. Our state-of-the-art manufacturing facilities located at Kullu (Himachal Pradesh), Dahej (Gujarat), and Tirupati (Andhra Pradesh), supported by the R&D Excellence Centre at Thane (near Mumbai) drive Fermenta’s comprehensive portfolio of premium vitamins, nutritional premixes and ingredients that exceed the unique needs and stringent regulatory standards of over 400 discerning customers in more than 60 countries. With decades of expertise at global-scale complex manufacturing, Fermenta also provides research-based custom solutions in green chemistry, APIs & intermediates, and environmental solutions.

Safe Harbour Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, market opportunities, competitive positioning, regulatory approvals, commercialization potential, the progress and results of research and development, potential project characteristics, project potential, and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements due to various factors including market conditions, regulatory changes, competitive dynamics, and other business risks. Fermenta Biotech Limited assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions, or other factors, except as and when required by applicable law.

Contact

Varadvinayak Khambete | varadvinayak.khambete@fermentabiotech.com

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026